Incorrect password
evipedia.ai Suggest Edit

Aged Garlic Extract for Health & Longevity

Evidence Review created on 05/02/2026 using AI4L / Opus 4.7

Also known as: AGE, Kyolic, Aged Garlic, Allium sativum Aged Extract

Motivation

Aged garlic extract (AGE) is a garlic preparation produced by soaking sliced raw garlic cloves in a dilute alcohol solution at room temperature for up to 20 months. The aging process converts the harsh, irritating sulfur compounds in raw garlic into stable, water-soluble, well-absorbed molecules that are largely odorless and gentle on the digestive tract. The result is a supplement chemically distinct from garlic powder, garlic oil, and allicin-standardized products, and with its own dedicated body of clinical research.

Among dietary supplements, AGE has accumulated an unusually deep record of human studies focused on cardiovascular health. Several decades of research have linked it to lower blood pressure and to favorable changes in arterial plaque, with a secondary stream of evidence covering immune function.

This review examines the clinical evidence for aged garlic extract across cardiovascular, immune, and related domains, and presents the practical details for evaluating it as part of a broader longevity strategy.

Benefits - Risks - Protocol - Conclusion

A curated selection of resources providing accessible overviews of aged garlic extract’s mechanisms, evidence, and practical applications.

  • How Aged Garlic Extract Can Slash Heart Disease Risk - Life Extension

    Detailed magazine feature on AGE’s cardiovascular benefits, covering coronary artery calcification slowing, blood pressure and cholesterol reduction, and the Harbor-UCLA research program led by Matthew Budoff that established AGE’s effect on plaque progression.

  • How (And Why) to Lower Your Blood Pressure Naturally - Chris Kresser

    Practitioner article on natural blood pressure strategies, including garlic supplementation with reference to clinical trial data showing meaningful systolic and diastolic reductions and a discussion of how preparations and standardization differ across products.

  • Anti-atherosclerotic Effect of Aged Garlic Extract: Mode of Action and Therapeutic Benefits - Miki et al., 2025

    Mechanism-focused narrative review covering AGE’s actions on endothelial dysfunction, oxidized LDL (low-density lipoprotein, the “bad” cholesterol most strongly linked to atherosclerosis), macrophage polarization, and platelet aggregation, with a synthesis of the clinical and animal evidence on coronary plaque burden. Conflict of interest: all authors are affiliated with Wakunaga Pharmaceutical, manufacturer of the Kyolic AGE brand; this conflict of interest is named again in the Conclusion and applies to a substantial portion of the AGE evidence base.

  • Antioxidant Health Effects of Aged Garlic Extract - Borek, 2001

    Foundational narrative review of AGE’s antioxidant biology, describing direct radical scavenging, induction of endogenous antioxidant enzymes, inhibition of LDL oxidation, and protection against oxidant-driven cardiovascular and neurological damage.

  • Aged Garlic Extract & Your Brain - Alzheimer’s Drug Discovery Foundation

    Evidence rating focused on AGE’s potential for cognitive aging and Alzheimer’s disease, summarizing preclinical findings on amyloid burden, oxidative stress, and neuroinflammation, alongside an honest account of the limited human cognitive trial data.

No dedicated long-form content on aged garlic extract specifically was found from Rhonda Patrick on foundmyfitness.com, Peter Attia on peterattiamd.com, or Andrew Huberman on hubermanlab.com. FoundMyFitness publishes news summaries citing the GarGIC trial but no in-depth AGE article. Huberman has discussed garlic/allicin in relation to TMAO and Alpha-GPC, but not AGE specifically.

Grokipedia

Aged garlic extract

Comprehensive entry describing AGE as a dietary supplement made from sliced garlic aged in aqueous alcohol for 10–20 months, its chemistry centered on S-allylcysteine and related sulfur compounds, its long-term safety record, and its commercial history through brands such as Kyolic.

Examine

Garlic benefits, dosage, and side effects

Examine’s garlic supplement guide treats AGE as one of the major studied preparations, covering the SAC (S-allylcysteine, the principal water-soluble organosulfur compound used as the standardized active marker for AGE) standardization (minimum 0.05% / 500 µg/g), the cardiovascular and immune evidence base, typical dosing of 600–1,200 mg, common side effects, and key drug interactions.

ConsumerLab

Garlic Supplement Reviews & Top Picks

Independent testing of garlic supplements, including aged garlic products, with quantification of allicin, alliin, and SAC. Among aged garlic supplements tested, SAC content per serving ranged from 944 mcg to 3,000 mcg, and at least one widely sold garlic product contained no detectable garlic compounds — underscoring the importance of third-party verification.

Systematic Reviews

A selection of recent systematic reviews and meta-analyses evaluating garlic supplementation, with emphasis on aged garlic extract specifically and on the cardiovascular, lipid, and inflammatory outcomes most relevant to the longevity audience.

Mechanism of Action

AGE acts through several complementary mechanisms, mediated primarily by S-allylcysteine (SAC), S-1-propenylcysteine (S1PC), and other water-soluble organosulfur compounds generated during aging:

  • Direct and induced antioxidant defense: SAC scavenges reactive oxygen species (ROS, unstable molecules that damage cells) and reactive nitrogen species directly, and activates the Nrf2/Keap1 pathway (Nrf2 is a transcription factor that turns on antioxidant genes; Keap1 is its repressor). This upregulates endogenous antioxidant enzymes — superoxide dismutase, catalase, glutathione peroxidase — and increases glutathione synthesis.
  • Anti-inflammatory signaling via NF-κB suppression: SAC and S1PC inhibit IKKβ kinase and modulate the TLR4 (toll-like receptor 4, a pattern-recognition receptor that triggers inflammatory signaling) and NF-κB (nuclear factor kappa B, a master transcription factor for inflammatory genes) pathways, reducing transcription of pro-inflammatory cytokines including TNF-α, IL-6 (interleukin-6, a cytokine involved in inflammation), and CRP.
  • AMPK activation: AGE increases phosphorylation of AMPK (AMP-activated protein kinase, a cellular energy sensor that promotes metabolic homeostasis), which contributes to glucose and lipid regulation and dampens inflammatory signaling.
  • Inhibition of LDL oxidation and macrophage foam-cell formation: AGE prevents the oxidation of LDL cholesterol — an early step in atherosclerotic plaque formation — and shifts macrophages away from the pro-inflammatory M1 phenotype, slowing foam-cell accumulation in the arterial wall.
  • Endothelial function and nitric oxide bioavailability: AGE enhances eNOS (endothelial nitric oxide synthase, the enzyme that produces nitric oxide in blood vessel walls) activity and reduces oxidative degradation of nitric oxide, promoting vasodilation, lower blood pressure, and improved arterial flexibility.
  • Selective antiplatelet activity: AGE inhibits platelet aggregation and adhesion through modulation of calcium signaling, with a milder effect than aspirin and without the bleeding signal seen for raw garlic in patients on warfarin.
  • Immunomodulation: AGE enhances proliferation and activity of NK (natural killer) cells and γδ-T cells (gamma-delta T cells, a small subset of T lymphocytes that act as a first-line defense at mucosal and barrier tissues), increases macrophage activity, and supports adaptive immunity, while simultaneously dampening excessive inflammation.

Pharmacological properties of the lead compounds: SAC and S1PC are well absorbed orally with high bioavailability (about 88–96% in animal models), reach peak plasma levels within 1–2 hours, and have plasma half-lives in the range of about 10 hours for SAC and somewhat shorter for S1PC. Both are excreted in urine in N-acetylated forms. AGE compounds are not strong inducers or inhibitors of major CYP450 (cytochrome P450, the family of liver enzymes responsible for metabolizing most drugs) enzymes, contributing to AGE’s relatively clean drug-interaction profile compared with raw garlic.

Historical Context & Evolution

Aged garlic extract’s path is unusual among supplements: a deliberately engineered product built around a single proprietary process, then validated by decades of independent clinical research.

  • Ancient use: Garlic (Allium sativum) has been used medicinally for over 5,000 years across Egyptian, Greek, Roman, Chinese, and Indian traditions. Hippocrates prescribed it; Egyptian pyramid laborers and Greek Olympic athletes received it for stamina and resilience. Raw garlic’s pungency and gastrointestinal irritation, however, limited its use as a standardized therapeutic.
  • 1955: Manji Wakunaga in Hiroshima, Japan, began work with Eugene Schnell on a process to retain garlic’s health-relevant compounds while eliminating odor and irritation. The result was extraction in dilute aqueous ethanol at room temperature for up to 20 months, yielding a stable, mostly odorless extract rich in water-soluble organosulfur amino acids.
  • 1972: Wakunaga of America was established in Hawaii, introducing AGE to the US market under the Kyolic brand.
  • 1990s–2000s: Matthew Budoff and colleagues at Harbor-UCLA Medical Center began the landmark series of randomized trials examining AGE’s effect on coronary artery calcification (CAC, a CT-measured marker of plaque burden), establishing for the first time that a dietary supplement could measurably slow the progression of subclinical atherosclerosis.
  • 2006: Macan and colleagues published a dedicated safety study showing that AGE did not increase bleeding events or destabilize INR in patients on warfarin therapy, addressing a long-standing concern about garlic and anticoagulants.
  • 2012: Nantz and colleagues published the immune RCT showing AGE enhances NK and γδ-T cell function and reduces cold and flu severity. The Zeb FAITH trial showed AGE plus CoQ10 (coenzyme Q10, a naturally occurring antioxidant involved in mitochondrial energy production) slowed CAC progression in firefighters.
  • 2016–2020: Matsumoto and colleagues, then Shaikh and colleagues and Wlosinska and colleagues, demonstrated AGE-induced reductions in low-attenuation plaque (the rupture-prone, vulnerable component of coronary plaques) in metabolic syndrome, type 2 diabetes, and unselected at-risk populations.
  • 2024–2026: Three large meta-analyses (Saadh 2024, Bashiri 2025, Behrouz 2026) consolidated the evidence on blood pressure, lipids, glycemic markers, and inflammation, with dose-response analyses pointing to 1,200–2,400 mg/day as the effective therapeutic range.

Throughout this history, the body of AGE evidence has been visibly shaped by Wakunaga, the manufacturer of Kyolic, both as a funder and as an institutional research partner. Independent investigator-initiated trials and meta-analyses now exist across multiple countries, but the conflict of interest is identified again in the Conclusion.

Expected Benefits

High 🟩 🟩 🟩

Blood Pressure Reduction

Multiple independent meta-analyses converge on AGE as effective for blood pressure in hypertensive adults. The Saadh 2024 meta-analysis (9 RCTs, 584 hypertensive participants) found AGE reduces systolic blood pressure by about 4 mmHg and diastolic by about 1.4 mmHg, with significant effects only at doses above 1,200 mg/day. The Bashiri 2025 dose-response meta-analysis of 19 trials of aged garlic specifically reported a 2.5 mmHg systolic reduction, with larger effects in cardiovascular disease populations. The earlier Ried 2020 meta-analysis of 12 trials (553 hypertensives) — which pools AGE and garlic powder — estimated reductions of about 8.3 mmHg systolic and 5.5 mmHg diastolic, comparable to first-line antihypertensive monotherapy. Effects are largest in those with treated but uncontrolled hypertension.

Magnitude: 2.5–8 mmHg systolic and 1.4–5.5 mmHg diastolic reduction in hypertensive adults; larger effects at doses above 1,200 mg/day and in those with poorly controlled blood pressure.

Lipid Profile Improvement

The Behrouz 2026 meta-analysis (108 RCTs, 7,137 participants) reports that garlic supplementation reduces total cholesterol by about 10.2 mg/dL, LDL-C by about 5.9 mg/dL, and triglycerides by about 5.8 mg/dL while raising HDL-C by about 2.2 mg/dL. The Bashiri 2025 aged-garlic-specific meta-analysis confirms LDL reductions of about 4.4 mg/dL and an effect on total cholesterol that approaches significance. Effects are largest in adults with elevated baseline lipids.

Magnitude: Total cholesterol reduction approximately 5–10 mg/dL (up to ~10.2 mg/dL in the Behrouz 2026 pooled analysis); LDL-C reduction approximately 4–6 mg/dL; HDL-C increase approximately 2 mg/dL; triglyceride reduction approximately 5–6 mg/dL.

Medium 🟩 🟩

Coronary Artery Calcification & Vulnerable Plaque Reduction

A coherent series of randomized trials from the Budoff group at Harbor-UCLA and collaborators has shown that AGE slows the progression of CAC and reduces low-attenuation plaque (LAP). Matsumoto et al. (2016; 55 patients with metabolic syndrome, 12 months) reported a 1.5% reduction in LAP in the AGE arm versus a 0.2% increase with placebo (P = 0.005). Shaikh et al. (2020; 66 type 2 diabetes patients, 12 months) confirmed LAP regression with AGE. Zeb et al. (2012; 65 intermediate-risk firefighters, 12 months) found AGE plus CoQ10 cut CAC progression nearly in half versus placebo. The Wlosinska 2020 European RCT (104 participants, 12 months) reproduced inhibited CAC progression with AGE alone.

Magnitude: Approximately 1.5 percentage point reduction in LAP versus a slight increase on placebo; roughly 45–50% reduction in the rate of CAC progression in 12-month trials.

Immune Function Enhancement & Cold/Flu Severity

The Nantz et al. 2012 RCT (120 healthy adults, 90 days, 2.56 g/day AGE) demonstrated significantly enhanced proliferation of NK cells and γδ-T cells after 45 days, and during cold and flu season the AGE group reported 21% fewer symptoms, 61% fewer days of suboptimal function, and 58% fewer missed work or school days versus placebo. Overall incidence was not significantly different.

Magnitude: 21% fewer reported symptoms; 61% fewer days of suboptimal function; 58% fewer missed days; significant increase in NK and γδ-T cell proliferation.

Systemic Inflammation Reduction

The Behrouz 2026 meta-analysis reports CRP reductions of about 1.6 mg/L and TNF-α reductions of about 3.9 pg/mL with garlic supplementation. The Mirzavandi 2020 meta-analysis of garlic on inflammatory markers found similar CRP reductions, with larger effects at doses above 1,200 mg/day and in subjects with elevated baseline inflammation. Several AGE-specific trials, including Zeb 2012 with CoQ10, show parallel CRP reductions over 12 months.

Magnitude: CRP reduction of approximately 0.8–1.6 mg/L; TNF-α reduction of approximately 3.9 pg/mL; effects largest in those with elevated baseline inflammation.

Low 🟩

Gingival Health

A randomized examiner-blind RCT by Zini et al. (2018; 134 participants, 4 months) found that daily AGE significantly reduced the Modified Gingival Index and Gingival Bleeding Index versus placebo (P < 0.001). A larger and longer trial in periodontitis (NCT06287424; 300 participants, 18 months) has now completed and is expected to provide the most definitive data on long-term oral effects. Evidence remains limited compared with the cardiovascular domain.

Magnitude: Statistically significant reduction in gingival inflammation and bleeding indices over 4 months versus placebo; magnitude in clinical units modest.

Aerobic Fitness in Middle-Aged Athletes

A double-blind, placebo-controlled RCT by Ried et al. (2025; 75 middle-aged recreational endurance athletes, 12 weeks) showed that Kyolic AGE significantly improved VO2max (maximal oxygen consumption, the gold-standard measure of aerobic fitness), aerobic power, lactate threshold, and recovery time versus placebo, alongside an improvement in pulse wave velocity (PWV, an arterial stiffness measure where higher values indicate stiffer arteries). The proposed mechanism is improved arterial flexibility translating to better oxygen delivery.

Magnitude: Statistically significant gains in VO2max, aerobic power, lactate threshold, and recovery time over 12 weeks; improved pulse wave velocity.

Vascular Endothelial Function & Arterial Stiffness

Several smaller RCTs report improvements in endothelial function and arterial elasticity with AGE. The FAITH trial (Larijani et al., 2012; 65 firefighters, 12 months) showed AGE plus CoQ10 improved vascular endothelial function and arterial elasticity versus placebo. Wlosinska 2020 reproduced improvements in arterial stiffness markers with AGE alone. Effect sizes are not consistently quantified across trials.

Magnitude: Not quantified in available studies.

Speculative 🟨

Neuroprotection and Cognitive Aging

Preclinical work and reviews (Sripanidkulchai 2020; Tedeschi 2022; Mony 2026; Afolayan 2025) report that AGE and SAC reduce β-amyloid burden, oxidative stress, and neuroinflammation in animal models of Alzheimer’s disease, with corresponding behavioral improvements. The mechanistic basis includes Nrf2 induction, NF-κB suppression, and direct antioxidant activity in cortex and hippocampus. No controlled human trials have evaluated AGE for cognitive aging or Alzheimer’s disease; this benefit therefore rests on mechanistic and animal evidence only.

Anti-Cancer and Cancer Prevention Activity

AGE and SAC induce apoptosis in cancer cell lines and reduce tumor formation in animal models. Epidemiological data from the large Linqu County intervention study following long-term garlic supplementation for gastric cancer prevention have been mixed. AGE-specific human cancer prevention or treatment trials remain limited; this benefit is best regarded as mechanistically supported but not clinically established.

Glycemic Control

The Behrouz 2026 meta-analysis reports modest reductions in fasting glucose (about 2.8 mg/dL), insulin (about 1.7 mU/L), and HOMA-IR (homeostatic model assessment of insulin resistance, an index that estimates insulin resistance from fasting glucose and insulin) with garlic supplementation. Most data come from mixed garlic preparations rather than AGE specifically. AGE-specific glycemic data are limited and effects modest.

Benefit-Modifying Factors

  • Baseline cardiovascular risk: Adults with hypertension, hypercholesterolemia, metabolic syndrome, type 2 diabetes, or elevated CRP consistently derive larger absolute benefits than already-optimized individuals. Subgroup analyses in the Behrouz, Bashiri, and Saadh meta-analyses show effect sizes scaling with baseline risk.
  • Genetic polymorphisms: Variations in antioxidant enzyme genes (SOD2 — superoxide dismutase 2, an enzyme that neutralizes superoxide; GPX1 — glutathione peroxidase 1, an enzyme that detoxifies hydrogen peroxide) and in eNOS may influence individual response to AGE’s antioxidant and vascular effects. Polymorphisms in CYP2E1 (cytochrome P450 2E1, a liver enzyme involved in metabolizing organosulfur compounds) may affect organosulfur metabolism. No pharmacogenomic guidelines exist.
  • Sex-based differences: Meta-analyses do not identify clear sex-based differences in cardiovascular response to AGE; both men and women benefit at similar doses.
  • Age-related considerations: Older adults may derive proportionally greater benefit because age increases oxidative stress, arterial stiffness, and immune dysregulation — the substrates AGE acts on. Trials in middle-aged and older adults have shown consistent effects; immune-relevant effects may be most valuable in those approaching or past 60.
  • Pre-existing cardiovascular conditions: Individuals with established coronary artery disease appear to gain the most distinctive benefit (slowing of plaque progression). Those with treated but uncontrolled hypertension represent the population with the strongest blood pressure evidence. Already well-controlled individuals on optimized medication regimens may experience smaller incremental gains.
  • Vitamin B12 status: A subset of the Ried trial data suggests B12 status affects responsiveness of blood pressure to garlic, with B12-replete subjects more likely to respond.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No high-evidence risks are established. AGE has been studied across multiple populations for up to 12 months with an excellent safety record. Trials consistently report no statistically significant increase in adverse events versus placebo. The aging process specifically eliminates the irritant compounds (allicin and related thiosulfinates) responsible for most raw-garlic side effects, and the dedicated warfarin safety trial found no increased bleeding.

Medium 🟥 🟥

Mild Gastrointestinal Discomfort

A minority of users experience mild bloating, gas, nausea, or loose stools, more commonly at doses above about 2,400 mg/day. Symptoms are typically transient and substantially less frequent than with raw garlic preparations. Most clinical trials report no statistically significant difference in gastrointestinal adverse events between AGE and placebo arms.

Magnitude: Reported by a small minority of users; no significant difference in GI adverse event rates between AGE and placebo in most clinical trials.

Low 🟥

Theoretical Increased Bleeding Risk with Anticoagulants ⚠️ Conflicted

Garlic preparations as a class have antiplatelet activity, raising the question of additive bleeding risk with warfarin, direct oral anticoagulants, antiplatelet drugs, or surgery. The Macan et al. 2006 dedicated safety RCT (48 patients on stable warfarin, 12 weeks of AGE 5 mL/day) found no destabilization of INR (international normalized ratio, a blood test that measures how long it takes blood to clot) and no increase in bleeding events. Case reports involving raw garlic preparations have not been reproduced with AGE. Because the antiplatelet mechanism is biologically plausible, conservative practice still recommends discussion with the prescriber and discontinuation around major surgery.

Magnitude: No increased bleeding events observed in the Macan warfarin safety RCT; theoretical risk based on antiplatelet mechanism.

Mild Garlic Odor

Although AGE is specifically engineered to be odorless, some users at higher doses report a mild garlic taste or breath, far less pronounced than with raw garlic, allicin-standardized, or garlic-oil products.

Magnitude: Minimal; far less than with raw garlic, allicin-based, or garlic oil preparations.

Speculative 🟨

Reduced Plasma Levels of Some HIV Protease Inhibitors

Garlic supplements have been reported to reduce plasma concentrations of saquinavir (an older HIV protease inhibitor, a class of antiretroviral medications that block HIV replication) through induction of intestinal P-glycoprotein (a membrane transporter that pumps drugs out of cells). The signal has been seen mainly with raw garlic preparations rather than AGE specifically; data on modern protease inhibitors and on AGE are sparse, but the precaution remains plausible.

Allergic Reactions

Rare cases of contact dermatitis and allergic reactions to garlic preparations have been reported, including occupational sensitization. Individuals with known allergy to garlic or other Allium species (onion, leek, shallot) should avoid AGE.

Risk-Modifying Factors

  • Anticoagulant or antiplatelet use: Patients on warfarin, direct oral anticoagulants, clopidogrel, or aspirin face the highest theoretical bleeding risk. The dedicated Macan study did not find INR instability with AGE specifically, but more frequent INR monitoring is reasonable in the first weeks of co-administration with warfarin.
  • Genetic polymorphisms: Variants in CYP2C9 and VKORC1 (warfarin pharmacogenetic loci that influence warfarin sensitivity) and in CYP2E1 may theoretically modify any pharmacokinetic interaction; this is not formally studied for AGE.
  • Baseline biomarker levels: Patients with INR at the upper end of the therapeutic range, or with already-low resting blood pressure (e.g., systolic below about 110 mmHg), warrant closer monitoring during the first weeks of higher-dose AGE.
  • Sex-based differences: No sex-based differences in adverse effect profile have been documented.
  • Age-related considerations: No age-specific increase in adverse events. AGE has been studied without additional safety concerns in older adults.
  • Pre-existing health conditions: Patients scheduled for surgery should pause AGE 7–10 days beforehand. Those with known Allium allergy should avoid AGE. Patients on HIV protease inhibitors should consult their prescriber.

Key Interactions & Contraindications

  • Anticoagulants and antiplatelets (caution; monitor INR for warfarin): Theoretical additive bleeding risk with warfarin, apixaban, rivaroxaban, dabigatran, clopidogrel, ticagrelor, and aspirin. The Macan AGE-specific study showed no INR destabilization or bleeding increase, but monitoring is prudent. Mitigating action: inform the prescriber, monitor INR during initiation if on warfarin, and pause AGE 7–10 days before elective surgery.
  • Antihypertensive drugs (caution; monitor blood pressure): ACE inhibitors (angiotensin-converting enzyme inhibitors, drugs that relax vessels by blocking angiotensin II production — e.g., lisinopril, ramipril), ARBs (angiotensin receptor blockers, drugs that block angiotensin II at its receptor — e.g., losartan, valsartan), calcium channel blockers (e.g., amlodipine), and diuretics may have additive blood-pressure-lowering effect with AGE. Mitigating action: monitor home blood pressure during the first 4–8 weeks; reduce antihypertensive dose with the prescriber if symptomatic hypotension (abnormally low blood pressure causing dizziness or fatigue) develops.
  • HIV protease inhibitors (caution): Saquinavir and possibly related drugs may have reduced plasma levels with concurrent garlic supplementation. Mitigating action: consult prescribing physician before initiation.
  • Hypoglycemic agents (caution; monitor glucose): Insulin, metformin (a first-line oral antidiabetic drug that reduces hepatic glucose output and improves insulin sensitivity), sulfonylureas (e.g., glipizide), and SGLT2 inhibitors (sodium-glucose cotransporter 2 inhibitors, oral antidiabetics that promote urinary glucose excretion — e.g., empagliflozin) may have additive glucose-lowering effects with AGE. Mitigating action: glucose monitoring during initiation.
  • Over-the-counter medications: Aspirin and NSAIDs (non-steroidal anti-inflammatory drugs such as ibuprofen and naproxen) may have additive antiplatelet effects with AGE. Mitigating action: avoid concurrent high-dose use; pause AGE before procedures.
  • Supplement interactions:
    • Additive blood-pressure-lowering supplements: magnesium, omega-3 fish oil (EPA/DHA), CoQ10, beetroot/nitrate, hawthorn extract — monitor for excessive blood pressure reduction when stacked.
    • Additive lipid-lowering supplements: berberine, red yeast rice, plant sterols, soluble fiber (psyllium) — monitor lipid panel and LDL-C.
    • Additive antiplatelet supplements: ginkgo biloba, high-dose fish oil, vitamin E at high doses, ginger, turmeric/curcumin — pause around procedures.
    • Synergistic, well-tolerated combination: AGE plus CoQ10 was the combination used in the Larijani/Zeb FAITH program; favorable additive effects on inflammation and CAC progression were reported.
  • Populations who should avoid AGE:
    • Individuals with known allergy to garlic or other Allium species
    • Patients within 7–10 days of scheduled surgery, dental extraction, colonoscopy with planned polypectomy, or any other invasive procedure (discontinue beforehand)
    • Patients on HIV protease inhibitor therapy without prescriber clearance
    • Pregnant or breastfeeding women at supplemental doses above culinary intake (>~500 mg/day; insufficient safety data; culinary garlic is not the same exposure)
    • Patients with diagnosed bleeding disorders (e.g., hemophilia, von Willebrand disease, ITP — immune thrombocytopenia, with platelet count <50 × 10⁹/L) or with significant gastrointestinal bleeding within the prior 90 days
    • Patients with INR >3.5 on chronic anticoagulation, until INR is restabilized

Risk Mitigation Strategies

  • Conservative initiation: Begin at 600–1,200 mg/day for the first 1–2 weeks to assess gastrointestinal tolerance and any blood pressure response, then titrate to 1,200–2,400 mg/day if no issues — mitigates GI discomfort and allows detection of excessive blood pressure reduction.
  • Disclosure to prescribers: Inform every clinician about AGE use, especially before being prescribed warfarin, DOACs (direct oral anticoagulants), antiplatelets, antihypertensives, antidiabetics, or HIV antiretrovirals — mitigates additive pharmacologic effects.
  • Procedural discontinuation: Stop AGE at least 7–10 days before scheduled surgery, dental extractions, colonoscopy with planned polypectomy, or other invasive procedures — mitigates theoretical additive antiplatelet bleeding risk.
  • INR monitoring with warfarin: If starting AGE while on warfarin, request an INR check at 1–2 weeks and again at 4 weeks — mitigates the theoretical (though not empirically observed in the Macan study) risk of INR destabilization.
  • Home blood pressure monitoring: When stacked with antihypertensive medication, measure home blood pressure twice daily for the first 2–4 weeks of AGE initiation — mitigates symptomatic hypotension.
  • Use of standardized AGE products: Choose products explicitly standardized to S-allylcysteine content (e.g., Kyolic) — mitigates the risk of receiving a product with negligible bioactive content as documented by ConsumerLab testing.
  • Take with meals: Splitting the daily dose between two meals further reduces any minor gastrointestinal discomfort and supports steady plasma levels of SAC.

Therapeutic Protocol

The protocols below summarize how AGE has been used in the trials that established its evidence base, primarily by the Budoff group, Wakunaga research collaborators, and independent investigators.

  • Standard cardiovascular protocol: 2,400 mg AGE per day, typically split as 1,200 mg twice daily with meals. This is the dose used in the Budoff series of CAC and LAP studies, the Wlosinska 2020 European RCT, and most of the cardiovascular meta-analysis trials. Lower doses of 600–1,200 mg/day have shown blood pressure benefits in some trials, but the Saadh 2024 meta-analysis specifically identified doses above 1,200 mg/day as the threshold for significant effects.
  • Immune protocol: 2.56 g/day used by Nantz et al. 2012 for immune cell function and cold/flu severity reduction; commonly approximated as 2,400 mg/day in practice.
  • Single dose vs split dose: Most trials use twice-daily dosing with breakfast and dinner. Given SAC’s plasma half-life of about 10 hours, twice-daily dosing maintains more consistent blood levels than once-daily dosing.
  • Best time of day: AGE has no diurnal preference. Taking it with meals is recommended primarily for tolerability.
  • Pharmacokinetic notes: SAC and S1PC reach peak plasma concentrations within 1–2 hours after oral administration, with high bioavailability. SAC half-life is approximately 10 hours; S1PC is somewhat shorter. Both are excreted in urine in N-acetylated form. AGE compounds are not strong CYP450 inducers or inhibitors at typical supplemental doses.
  • Genetic polymorphisms: No pharmacogenomic dosing guidelines exist. Theoretical considerations include CYP2E1, eNOS, and antioxidant enzyme variants.
  • Sex-based differences: No sex-specific dose adjustments are established; trials use the same doses for men and women.
  • Age-related considerations: No age-based dose adjustments are required. Older adults may benefit from initiation at 600–1,200 mg/day to assess tolerance and to detect any additive antihypertensive effect.
  • Baseline biomarker tracking: Useful baselines include lipid panel, blood pressure (office and home), hs-CRP (high-sensitivity C-reactive protein, a more sensitive form of CRP testing for low-grade inflammation), HbA1c (glycated hemoglobin, a marker of average blood glucose over 2–3 months) if metabolic effects are of interest, and a CAC score in those with established or significant cardiovascular risk.
  • Pre-existing health conditions: Patients on warfarin should have INR rechecked at 1–2 and 4 weeks. Patients with active bleeding disorders should avoid AGE. Those with active coronary disease or recent percutaneous coronary intervention should coordinate with their cardiologist.

Discontinuation & Cycling

  • Lifelong vs short-term use: AGE can be used as a long-term daily supplement for ongoing cardiovascular and inflammatory protection or seasonally (e.g., 90 days during cold and flu season). The longest controlled trials are 12 months; epidemiological cohorts and the Linqu trial extend exposure to several years without safety concerns.
  • Withdrawal effects: None reported. Blood pressure, lipids, and inflammatory markers will gradually return toward pre-supplementation values over weeks after discontinuation.
  • Tapering protocol: No taper is required. AGE can be stopped at any time, including abruptly for an upcoming procedure.
  • Cycling for efficacy: No evidence of tolerance has been observed; effects are mediated by direct biochemistry and gene expression changes rather than receptor downregulation. Continuous daily use is the approach used in essentially all trials of cardiovascular endpoints.

Sourcing and Quality

  • Standardization to S-allylcysteine (SAC): The single most important quality criterion. ConsumerLab testing found SAC content per serving among aged garlic products ranging from 944 mcg to 3,000 mcg, with at least one widely sold garlic product containing no detectable garlic compounds at all. Choose products that explicitly state SAC content per serving.
  • Kyolic (Wakunaga): The reference brand and the brand used in the majority of clinical trials. Kyolic AGE is produced from organically grown garlic aged in stainless steel containers for up to 20 months at the Torrance, California facility (cGMP — current Good Manufacturing Practice — and ISO 9001:2015 certified). Cardiovascular formulas (Formula 100, Reserve) are most commonly used in clinical research; Formula 104 adds lecithin, Formula 107 adds vitamin C, vitamin D, and astragalus for immune use.
  • Third-party testing: Prefer products that carry NSF, USP, or ConsumerLab verification, in addition to a stated SAC content.
  • Avoid substituting raw-garlic products: Allicin-standardized garlic powder, garlic oil, and “fresh garlic” capsules are chemically distinct from AGE. Allicin is unstable, may not survive digestion intact, and the cardiovascular and immune evidence reviewed here applies specifically to AGE rather than to these alternatives.
  • Storage and freshness: AGE is stable in capsule and liquid form when stored away from heat and direct sunlight; replace bottles past their stated expiration date.

Practical Considerations

  • Time to effect: Blood pressure changes typically appear within 2–4 weeks; lipid changes within 8–12 weeks; CRP and other inflammatory markers within 4–8 weeks; immune cell changes by 45 days in the Nantz trial; CAC and LAP changes require 12 months of continuous use to detect.
  • Common pitfalls:
    • Confusing preparations: Treating AGE, garlic powder, raw garlic capsules, garlic oil, and black garlic as equivalent. The cardiovascular evidence base reviewed here applies specifically to AGE.
    • Underdosing: Taking 600 mg/day and expecting blood-pressure or plaque effects shown only at 1,200–2,400 mg/day.
    • Expecting drug-equivalent effects: AGE’s blood pressure and lipid effects are statistically meaningful but typically smaller than first-line medications; AGE is best understood as part of a stack rather than as monotherapy in higher-risk individuals.
    • Buying unstandardized products: Many products lack SAC standardization and may deliver negligible bioactive content.
  • Regulatory status: AGE is sold as a dietary supplement in the United States; Kyolic AGE has self-affirmed GRAS (Generally Recognized as Safe) status. In Japan, AGE products are classified within the Foods for Specified Health Uses framework.
  • Cost and accessibility: Kyolic AGE at the cardiovascular dose of 2,400 mg/day typically costs approximately $15–30 USD per month, widely available through pharmacies, supplement retailers, and online channels.

Interaction with Foundational Habits

  • Sleep: AGE has no direct sedating or stimulating effect, and no clinical effect on sleep architecture has been reported. Indirect effects on sleep quality through lower nocturnal blood pressure or reduced systemic inflammation are plausible but not specifically demonstrated. Timing relative to sleep is not constrained.
  • Nutrition: AGE is compatible with all dietary patterns and does not deplete known nutrients. Cardiovascular benefits are likely additive with a Mediterranean-pattern diet, soluble fiber intake, and omega-3 sufficiency. AGE does not replace dietary garlic intake, and there are no specific food–supplement interactions of clinical concern.
  • Exercise: AGE may potentiate aerobic adaptations through improved arterial flexibility and oxygen delivery. The Ried 2025 RCT in middle-aged endurance athletes (75 participants, 12 weeks) showed significant improvements in VO2max, aerobic power, lactate threshold, and recovery time with Kyolic AGE versus placebo. AGE does not blunt resistance-training adaptation. No specific timing relative to workouts is required.
  • Stress management: AGE has no documented direct effect on cortisol or HPA-axis (hypothalamic-pituitary-adrenal axis, the main neuroendocrine system controlling the stress response) function. Indirect benefits in chronic-stress contexts — where elevated oxidative stress and inflammation are present — are mechanistically plausible but not specifically tested.

Monitoring Protocol & Defining Success

Baseline labs and assessments before starting AGE typically include the following, depending on the goal:

  • Lipid panel: total cholesterol, LDL-C, HDL-C, triglycerides
  • Office and home blood pressure
  • hs-CRP for inflammation
  • Fasting glucose and HbA1c if metabolic effects are of interest
  • CAC (coronary artery calcium) score when established or significant cardiovascular risk is present and CT access allows
  • INR for patients on warfarin

Ongoing monitoring can be performed at 4 weeks (blood pressure), 8–12 weeks (lipids, hs-CRP, fasting glucose), 6 months (full panel reassessment), and annually thereafter. CAC progression, where used, is reassessed at 12 months.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Total cholesterol < 180 mg/dL Tracks lipid response to AGE Conventional reference: < 200 mg/dL; fasting 9–12 h; baseline, 8–12 weeks, 6 months
LDL-C < 80 mg/dL (< 70 mg/dL if higher cardiovascular risk) Primary lipid risk marker Conventional reference: < 130 mg/dL; calculated from same fasting panel
HDL-C > 50 mg/dL (men), > 60 mg/dL (women) Tracks protective lipid response Conventional reference: > 40 mg/dL (men), > 50 mg/dL (women)
Triglycerides < 80 mg/dL Tracks lipid and metabolic response Conventional reference: < 150 mg/dL; fasting 9–12 h
Systolic BP (home, seated) < 120 mmHg Tracks antihypertensive response Conventional reference: < 140 mmHg; same arm, same time, twice daily for 7 days
Diastolic BP (home, seated) < 75 mmHg Tracks antihypertensive response Conventional reference: < 90 mmHg; paired with systolic measurement
hs-CRP < 1.0 mg/L Tracks systemic inflammation Conventional reference: < 3.0 mg/L; not a fasting test; recheck 8–12 weeks
Fasting glucose 75–85 mg/dL Tracks glycemic effect Conventional reference: < 100 mg/dL; fasting 8–12 h
HbA1c < 5.3% Tracks longer-term glycemia Conventional reference: < 5.7%; recheck at 3–6 months
INR (if on warfarin) Per individual target Detects any pharmacokinetic destabilization Recheck 1–2 and 4 weeks after AGE initiation
CAC (if indicated) Lowest age-stratified percentile feasible Tracks plaque burden CT-based; reassessed at 12 months in higher-risk individuals

Qualitative markers to monitor:

  • Home blood pressure trend over rolling 7-day windows
  • Gastrointestinal comfort and bowel habits (especially in first month)
  • Cold and flu frequency, duration, and severity during respiratory virus season
  • Energy, training tolerance, and recovery in active individuals
  • Gum health and bleeding during brushing and flossing
  • Subjective vitality and overall well-being

Emerging Research

Several lines of ongoing and emerging research may meaningfully expand or refine AGE’s evidence base.

  • Long-term periodontitis: A 300-participant RCT (NCT06287424) of AGE at different doses for periodontitis over 18 months has now completed, providing the longest oral-health dataset for AGE.
  • Coronary atherosclerosis in type 2 diabetes: A completed RCT of AGE on coronary plaque progression in type 2 diabetes (NCT03931434, 88 participants) extends the Budoff plaque-regression series into a higher-risk population.
  • CAC, microcirculation, and proteomics: A completed European RCT (NCT03860350, 100 participants) of AGE on CAC progression, inflammatory biomarkers, and microcirculation introduces laser speckle imaging and urinary proteomics as new readouts of AGE’s vascular effects.
  • Aerobic fitness and cardiovascular proteomics: The Ried 2025 RCT (2025) reported, alongside aerobic fitness gains, decreases in urinary proteomic biomarkers associated with cardiovascular events in middle-aged endurance athletes — opening a new domain linking arterial flexibility, exercise capacity, and event risk.
  • Pro-inflammatory gene expression as a target: A 2025 review by Agostinelli et al. (2025) synthesized the molecular basis for AGE’s effects on TLR4–NF-κB signaling and proposed disease-specific targets including lung disease, neurological disease, and cancer.
  • Anti-atherosclerotic mode of action: A mechanism-focused review by Miki et al. (2025) consolidated the evidence on AGE’s actions on endothelial function, macrophage polarization, and platelet aggregation in atherosclerosis.
  • Pharmacokinetics of sulfur-containing AGE compounds: The Nakamoto et al. review (2025) characterized SAC, S1PC, S-methylcysteine, and S-allylmercaptocysteine pharmacokinetics, supporting future dose optimization.
  • Cognitive aging and Alzheimer’s disease models: Mony et al. (2026) reported AGE attenuated age-associated memory impairment in animal models via molecular changes in cortex and hippocampus; combined with the existing reviews, this strengthens the rationale for human cognitive trials.
  • Counter-evidence to monitor: Larger and more methodologically rigorous independent trials may reduce the AGE-specific blood pressure effect estimate, particularly in already-medicated populations. The Bashiri 2025 meta-analysis already found a smaller systolic effect (~2.5 mmHg) than the Ried 2020 meta-analysis (~8.3 mmHg), suggesting effect sizes may continue to attenuate as the literature matures.

Conclusion

Aged garlic extract is the most extensively studied garlic preparation, with a multi-decade clinical record concentrated on cardiovascular health. The strongest evidence supports modest reductions in blood pressure, cholesterol, triglycerides, and inflammatory markers, with the largest gains in those starting from elevated baseline risk. Its most distinctive finding is a consistent slowing of coronary artery calcification and reduction in vulnerable, rupture-prone plaque across multiple randomized trials — a signal rarely seen with dietary supplements. Medium-strength evidence supports immune function enhancement and reduced cold and flu severity, plus broad anti-inflammatory effects. Lower-strength but interesting signals exist for gum health, aerobic fitness, and arterial elasticity. Neuroprotective and anti-cancer effects remain largely preclinical.

Practical use centers on a dose of about 1,200–2,400 mg per day of aged garlic extract standardized to its key active compound, divided across two meals. Safety has been excellent across populations and durations studied to date, including a dedicated study in patients on long-term blood-thinning therapy; pausing around surgery and reasonable monitoring with concurrent blood-pressure-lowering or anticoagulant drugs are the main precautions.

The evidence base is shaped in part by Wakunaga, the manufacturer of Kyolic, which has funded or co-led many of the foundational trials, although a substantial body of independent randomized trials and meta-analyses now exists. For longevity-oriented adults, aged garlic extract is best framed as a well-tolerated complementary intervention within a broader cardiovascular and metabolic strategy.

Top - Benefits - Risks - Protocol